Deferasirox (DSX) is the principal option currently available for iron-chelation-therapy (ICT), principally in the management of myelodysplastic syndromes (MDS), while in primary myelofibrosis (PMF) the expertise is limited. We analyzed our experience in 10 PMF with transfusion-dependent anemia, treated with DSX from September 2010 to December 2013. The median dose tolerated of DSX was 750 mg/day (10 mg/kg/day), with 3 transient interruption of treatment for drug-related adverse events (AEs) and 3 definitive discontinuation for grade 3/4 AEs. According to IWG 2006 criteria, erythroid responses with DSX were observed in 4/10 patients (40%), 2 of them (20%) obtaining transfusion independence. Absolute changes in median serum ferritin levels (Delta ferritin) were greater in hematologic responder (HR) compared with non-responder (NR) patients, already at 6 months of ICT respect to baseline. Our preliminary data open new insights regarding the benefit of ICT not only in MDS, but also in PMF with the possibility to obtain an erythroid response, overall in 40 % of patients. HR patients receiving DSX seem to have a better survival and a lower incidence of leukemic transformation (PMF-BP). Delta ferritin evaluation at 6 months could represent a significant predictor for a different survival and PMF-BP. However, the tolerability of the drug seems to be lower compared to MDS, both in terms of lower median tolerated dose and for higher frequency of discontinuation for AEs. The biological mechanism of action of DSX in chronic myeloproliferative setting through an independent NF-κB inhibition could be involved, but further investigations are required.
Elli, E., Belotti, A., Aroldi, A., Parma, M., Pioltelli, P., & Pogliani, E. (2014). Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 6(1) [10.4084/MJHID.2014.042].
|Citazione:||Elli, E., Belotti, A., Aroldi, A., Parma, M., Pioltelli, P., & Pogliani, E. (2014). Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 6(1) [10.4084/MJHID.2014.042].|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis|
|Autori:||Elli, E; Belotti, A; Aroldi, A; Parma, M; Pioltelli, P; Pogliani, E|
ELLI, ELENA MARIA (Corresponding)
|Data di pubblicazione:||2014|
|Rivista:||MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.4084/MJHID.2014.042|
|Appare nelle tipologie:||01 - Articolo su rivista|